Offering of certification mark for bioequivalence-tested drugs sought

Published: 2003-05-02 06:59:00

Updated: 2003-05-02 06:59:00

The Korea Food and Drug Administration has recently announced it plans on the offering of certification mark for bioequivalence-tested drugs in a bid to promote the active participation of many pharmaceutical firms in the bioequivalence testing and let the people be better informed of the efficac...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK